Bridgepoint's €1.2bn CV gives a 2017 fund a new clock
The Pantheon-led transfer shows secondaries capital absorbing seasoned direct loans, turning fund maturity from a selling deadline into a choice.
A fund raised in 2017 is nine years old, and nine is the age when a European direct lender's conversation normally turns from deployment to realisation; Bridgepoint Credit answered that conversation with a continuation vehicle, moving €1.2bn (about £1bn) of loans out of Bridgepoint Direct Lending II and into a structure led by the secondaries investor Pantheon, which Bridgepoint said was oversubscribed. Alternative Credit Investor first reported the transfer.
Investors in the new vehicle — BDL II's existing limited partners plus new names drawn in by the deal — get an election rather than a forced sale: they can cash out or roll into a portfolio of European middle-market businesses. Paul Johnson, deputy managing partner at Bridgepoint Credit and chairman of its direct lending business, described the vehicle as giving investors a 'choice', with realisation on one side and continued exposure on the other.
What they are choosing over is a book typical of a scaled European lender's late-2010s vintage: senior secured credits weighted toward healthcare, services and technology, with borrowers across the UK, the DACH region, the Nordics, Benelux and the French middle market. Bridgepoint keeps managing the portfolio and will oversee each position until realisation. Evercore, which in August helped Star Mountain close the first collateralised fund obligation, acted as financial adviser, with Kirkland & Ellis counsel to Bridgepoint Credit and Proskauer to Pantheon. The coverage does not say how the portfolio was priced relative to its marks in BDL II, the number that would determine how much of the value creation lands with sellers rather than new investors.
The structure has become familiar as private credit funds, like buyout funds before them, have outlived their original terms: Alternative Credit Investor notes recent large transactions of the same shape, including $3.2bn of Crescent Capital assets sold into a Pantheon-led vehicle and a $2.3bn continuation fund for Benefit Street Partners led by Coller Capital. Pantheon's Toni Vainio, partner and head of European private credit, said the deal reflected growing demand for scaled GP-led solutions in private credit, giving his firm a way into a seasoned portfolio of high-quality European middle-market loans.
Direct lenders will read the deal through the calendar: a GP-led continuation vehicle is the asset-side mirror of the CLO resets that managers have used to keep funding open as new issuance slowed, and, as this publication has argued, the reset wave has become private credit's funding valve. Bridgepoint itself reset its debut CLO for €307.85m in August, pushing reinvestment to 2031; where the reset stretches the liability, the CV stretches the asset, so no position has to be liquidated because the fund that held it reached a birthday, and the same manager keeps overseeing each credit until it pays off.
Secondaries buyers do not pay up for books they could replace at comparable risk in the primary market, so the oversubscription Bridgepoint reported carries information: a book with years of payment history has become a better risk than the marginal new deal a direct lender can underwrite at current market terms. That is a judgment about origination, and allocators are making it with capital: if fresh European middle-market paper were the best risk-adjusted entry point, a CV marketing process would not run oversubscribed.
For allocators, the growth of these vehicles changes the terms on which a direct lending fund should be underwritten: the old assumption that a decade-old fund returns capital as loans pay off has given way to refinancings and extensions that keep positions alive well past that. The CV formalises the extension: instead of asking a committee to push out a fund's life, the manager runs what is in effect a market test, sets a new valuation and lets each limited partner choose to stay or leave, a better mechanism than a silent extension and one that produces a price.
The numbers put the deal in proportion: Bridgepoint reported $24.2bn in regulated assets at the start of September, and Pantheon, the lead investor, carried $87.7bn, according to PCD records. That makes €1.2bn a meaningful slice of Bridgepoint's book but not a bet-the-firm one, and for Pantheon absorbing a seasoned portfolio of this kind is a portfolio construction decision rather than a stretch. For other direct lenders with 2017 and 2018 vintages ageing on the books, the template is now public: hold the portfolio, give investors the choice, let secondaries buy the tail. Bridgepoint bought time to let this book mature into realisation, and the surprising part is that the market for that time was oversubscribed.
A book with years of payment history has become a better risk than the marginal new deal a direct lender can underwrite at current market terms.